COST-UTILITY ANALYSIS OF VALSARTAN VERSUS VALSARTAN PLUS HYDROCHLOROTHIAZIDE IN PATIENTS WITH HYPERTENSION IN THE US

被引：0
|
作者：
Pednekar, P. [1 ]
机构：
[1] Univ Sci, Philadelphia, PA USA
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.04.374
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV52
引用
收藏
页码：S62 / S62
页数：1
相关论文
共 50 条
  • [1] Economic evaluation of telmisartan, valsartan and losartan in combination with hydrochlorothiazide for treatment of mild-to-moderate hypertension in Greece: a cost-utility analysis
    Kourlaba, Georgia
    Fragoulakis, Vassilios
    Theodoratou, Dorina
    Maniadakis, Nikos
    JOURNAL OF PHARMACEUTICAL HEALTH SERVICES RESEARCH, 2013, 4 (02) : 81 - 88
  • [2] Cost-utility analysis of valsartan, enalapril, and candesartan in patients with heart failure in Iran
    Ramin Ravangard
    Farideh Sadat Jalali
    Marjan Hajahmadi
    Abdosaleh Jafari
    Health Economics Review, 13
  • [3] Cost-utility analysis of valsartan, enalapril, and candesartan in patients with heart failure in Iran
    Ravangard, Ramin
    Jalali, Farideh Sadat
    Hajahmadi, Marjan
    Jafari, Abdosaleh
    HEALTH ECONOMICS REVIEW, 2023, 13 (01)
  • [4] Effects of Telmisartan with Hydrochlorothiazide versus Valsartan with Hydrochlorothiazide in Patients with Moderate-to-Severe Hypertension
    Marfatia, Ravi
    White, William B.
    Schumacher, Helmut
    INTERNATIONAL JOURNAL OF HYPERTENSION, 2012, 2012
  • [5] PHARMACOECONOMIC ANALYSIS OF AZILSARTAN MEDOXOMIL plus CHLORTALIDONE IN PATIENTS WITH ARTERIAL HYPERTENSION: COMPARISON WITH VALSARTAN plus HYDROCHLOROTHIAZIDE, TELMISARTAN plus HYDROCHLOROTHIAZIDE, LOSARTAN plus HYDROCHLOROTHIAZIDE AND IRBESARTAN plus HYDROCHLOROTHIAZIDE
    Chiu-Ugalde, J.
    Vargas, J. A.
    Asbun-Bojalil, J.
    Gay-Molina, J. G.
    Figueroa-Rodriguez, A.
    Ortiz-Blas, L.
    Zamora Mucino-Arroyo, A. J.
    Lopez-Alvarenga, J. C.
    VALUE IN HEALTH, 2014, 17 (03) : A113 - A113
  • [6] IMPACT OF VALSARTAN AND COMBINATION OF VALSARTAN AND HYDROCHLOROTHIAZIDE ON ERECTILE DYSFUNCTION IN PATIENTS WITH MILD TO MODERATE HYPERTENSION
    Salobir, B.
    Brguljan-Hitij, J.
    Dolenc, P.
    Chazova, I.
    Sirenko, Y.
    Vincelj, J.
    Widimsky, J.
    Barbic-Zagar, B.
    Accetto, R.
    JOURNAL OF HYPERTENSION, 2016, 34 : E275 - E275
  • [7] COST-UTILITY ANALYSIS OF SACUBITRIL/VALSARTAN FOR THE TREATMENT OF CHRONIC HEART FAILURE IN GREECE
    Stafylas, P.
    Farmakis, D.
    Kourlaba, G.
    Giamouzis, G.
    Chatzikou, M.
    Kossiva, E.
    Maniadakis, N.
    Parissis, J.
    VALUE IN HEALTH, 2016, 19 (07) : A654 - A654
  • [8] Efficacy and effectiveness of valsartan/amlodipine and valsartan/amlodipine/hydrochlorothiazide in hypertension: randomized controlled versus observational studies
    Sison, Jorge
    Rios Vega, Rosa Maria
    Dayi, Hu
    Bader, Giovanni
    Brunel, Patrick
    CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (03) : 501 - 515
  • [9] Spectrophotometric analysis of valsartan and hydrochlorothiazide
    Erk, N
    ANALYTICAL LETTERS, 2002, 35 (02) : 283 - 302
  • [10] Sacubitril-valsartan for the treatment of hypertension in China: A cost-utility analysis based on meta-analysis of randomized controlled trials
    Lou, Yake
    Yu, Ying
    Liu, Jinxing
    Huang, Jing
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
12345